INCY

Q: What is the price of Incyte (INCY) today?

The current price of Incyte (INCY) is $ 97.82, representing a 68.05% gain over the past year. The stock began the year trading around $ 98.77 and is currently priced at $ 97.82. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Incyte (INCY) pay dividends?

Incyte (INCY) did not pay dividends over the past year.

Q: Is Incyte (INCY) a good investment?

Incyte (INCY) is currently trading at $ 97.82 with a P/E ratio of 14.98%. This represents a 11,285% premium compared to its historical average P/E. Over the past year, the stock has gained 68.05 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 68.05%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Incyte Corporation

Price

$ 97.82

return (12m)

68.05%

p/e

14.98

p/bv

3.73

DIVIDEND YIELD

0.00%

INCY price

INCY

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment INCY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

7.76%

3 months

-7.90%

1 year

68.05%

2 years

86.86%

5 years

15.46%

10 years

27.42%

Fundamentals INCY

review the fundamentals of Incyte shares

P/E

14.98

Sector: -4.11 Industry: -4.11

P/S (PSR)

3.75

Sector: -3.78 Industry: -3.78

P/BV

3.73

Sector: 1.95 Industry: 1.95

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

18.49%

Sector: -61.23% Industry: -61.23%

ROE

24.90%

Sector: -60.44% Industry: -60.44%

ROIC

39.78%

Sector: -1,165.26% Industry: -1,165.26%

NET MARGIN

25.03%

Sector: -39.16% Industry: -39.16%

GROSS MARGIN

92.76%

Sector: 37.92% Industry: 37.92%

OPERATING MARGIN

26.12%

Sector: -39.32% Industry: -39.32%

EV/EBITDA

10.95

Sector: -4.00 Industry: -4.00

EV/EBIT

11.56

Sector: -4.22 Industry: -4.22

PRICE-TO-ASSETS

2.77

Sector: 1.44 Industry: 1.44

BVPS

26.23

Sector: 1.88 Industry: 1.88

EPS

6.53

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.74

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.26

Sector: 0.38 Industry: 0.38

CAGR REVENUE 5 YEARS

11.48%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

6.29%

Sector: - Industry: -

FAIR VALUE OF Incyte ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 97.82

Fair Value

$ 0.00

Upside/Downside Return potential.

-36.54%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals INCY

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	20.93	7.08	33.81%	2.23%	$ 560.91 B	28.46%
PFE	20.17	1.68	8.35%	6.24%	$ 156.71 B	12.42%
ABBV	87.13	0.00	0.00%	3.19%	$ 368.21 B	6.91%
NVO	11.49	5.92	51.50%	4.60%	$ 179.95 B	33.05%
MRK	16.19	0.00	0.00%	2.79%	$ 295.53 B	28.08%
AZN	31.07	6.52	20.99%	1.56%	$ 317.64 B	17.41%
GILD	20.09	7.56	37.62%	2.32%	$ 170.95 B	28.90%
BMY	17.19	-3.56	-20.72%	4.18%	$ 121.26 B	14.64%
ZTS	20.05	16.09	80.25%	1.66%	$ 53.60 B	28.23%
REGN	17.16	2.47	14.41%	0.48%	$ 77.31 B	31.41%
HALO	25.80	167.51	649.21%	0.00%	$ 8.18 B	22.69%
AMGN	24.84	22.12	89.06%	2.72%	$ 191.51 B	20.98%
MCK	24.55	-1,076.41	-4,383.84%	0.37%	$ 106.56 B	1.09%
VRTX	28.35	6.00	21.18%	0.00%	$ 112.06 B	32.94%
CAH	30.39	-18.70	-61.56%	0.95%	$ 50.50 B	0.68%
HRMY	10.77	1.96	18.24%	0.00%	$ 1.71 B	18.27%
ADMA	17.83	5.49	30.78%	0.00%	$ 2.62 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

INCY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Incyte

Incyte Corporation

Average Investor10 user rating

4.0 (5 people)

United States

35 years

Founded: 1991

1993

Time since IPO - 33 years

1.773

Employees

Incyte Corporation (United States) is listed on the Nasdaq and has a market capitalization of $19.27 Billions, with shareholders equity totaling $5.17 Billions.

The company employs approximately 1.773 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Incyte Corporation reported $5.14 Billions in revenue, generating net income of $1.29 Billion.

Key financial metrics include a P/E ratio of 14.98, a price-to-book (P/B) ratio of 3.73, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INCY.

Market cap

$ 19.27 Billions

Net worth

$ 5.17 Billions

$ 5,167,480,000.00

Assets

$ 6.96 Billions

$ 6,957,970,000.00

Total Shares Outstanding

197.00 Millions

197,000,000

Average Daily Trading Volume

$ 1.69 Million

$ 1,693,038.12

Sector

Health Care

Industry

Biotechnology

INCY

revenue by Business Segment Incyte

Revenue by Region Incyte

INCY revenue and profits

Financial Results INCY

DRAG THE FRAME TO SEE MORE DATA

INCY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 866.38 24,78% (12M)

P/E

24.55

0.37%

ROE

-4,383.84%

P/BV

-1,076.41

CAH - Cardinal Health

$ 213.99 60,64% (12M)

P/E

30.39

0.95%

ROE

-61.56%

P/BV

-18.70

JNJ - Johnson & Johnson

$ 234.18 53,74% (12M)

P/E

20.93

2.23%

ROE

33.81%

P/BV

7.08

PFE - Pfizer

$ 27.56 33,52% (12M)

P/E

20.17

6.24%

ROE

8.35%

P/BV

1.68

ABBV - AbbVie

$ 208.38 25,43% (12M)

P/E

87.13

3.19%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 119.07 58,20% (12M)

P/E

16.19

2.79%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 204.80 55,80% (12M)

P/E

31.07

1.56%

ROE

20.99%

P/BV

6.52

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 866.38 24,78% (12 M)

P/L

24.55

0.37%

ROE

-4,383.84%

P/VP

-1,076.41

CAH - Cardinal Health

$ 213.99 60,64% (12 M)

P/L

30.39

0.95%

ROE

-61.56%

P/VP

-18.70

JNJ - Johnson & Johnson

$ 234.18 53,74% (12 M)

P/L

20.93

2.23%

ROE

33.81%

P/VP

7.08

PFE - Pfizer

$ 27.56 33,52% (12 M)

P/L

20.17

6.24%

ROE

8.35%

P/VP

1.68

ABBV - AbbVie

$ 208.38 25,43% (12 M)

P/L

87.13

3.19%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 119.07 58,20% (12 M)

P/L

16.19

2.79%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 204.80 55,80% (12 M)

P/L

31.07

1.56%

ROE

20.99%

P/VP

6.52

Frequently Asked Questions

What is the price of Incyte (INCY) today?

The current price of Incyte (INCY) is $ 97.82, representing a 68.05% gain over the past year. The stock began the year trading around $ 98.77 and is currently priced at $ 97.82. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Incyte (INCY) pay dividends?

Incyte (INCY) did not pay dividends over the past year.

Is Incyte (INCY) a good investment?

Incyte (INCY) is currently trading at $ 97.82 with a P/E ratio of 14.98%. This represents a 11,285% premium compared to its historical average P/E. Over the past year, the stock has gained 68.05 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 68.05%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Incyte (INCY) stock?

You can buy Incyte (INCY) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol INCY and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Incyte (INCY) yield today?

Over the past month, Incyte (INCY) has returned 7.76% — 68.05% over the past year, and 15.46% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Incyte (INCY) today at the current price of $ 97.82 your total investment would be $ 9,782.00.

Based on historical performance, the investment would have grown to approximately:

$ 16,438.65 after 1 year
$ 11,294.30 after 5 years
$ 12,464.22 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

INCY

Incyte Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment INCY

review the fundamentals of Incyte shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Incyte

Incyte Corporation

United States

35 years

1993

1.773

PROFIT X PRICE INCY

Financial Results INCY

INCY cash flow

Asset, Revenue and Profit Growth - INCY

INCY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions